Melkart

Vildagliptin, the active ingredient in Melkart, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is prescribed to improve glycaemic control in adults with type 2 diabetes mellitus by enhancing insulin secretion and reducing glucagon release after meals.

GNH USA supplies Melkart as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring product quality through stringent manufacturing standards and reliable global logistics.

Melkart, a DPP‑4 inhibitor, is used in the management of disorders related to impaired glucose regulation.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - As adjunct to diet and exercise: improves overall HbA1c when lifestyle measures are insufficient. - In combination therapy (e.g., with metformin): provides additional glycaemic reduction for patients not reaching targets on monotherapy.

Adverse reactions may occur with any medication. Monitoring and reporting are essential.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Dizziness: occasional light‑headedness. - Upper respiratory tract infection: mild cold‑like symptoms. - Diarrhoea: loose stools, usually self‑limiting. - Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions (anaphylaxis): rash, swelling, difficulty breathing. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Severe skin reactions (Stevens‑Johnson syndrome, toxic epidermal necrolysis): blistering and detachment of skin. - Bullous pemphigoid: chronic blistering skin disease. - Marked hypoglycaemia: especially when used with insulin secretagogues.

Before initiating therapy, consider patient‑specific factors and monitor appropriately.

- Renal impairment: dose adjustment may be required; assess creatinine clearance. - Hepatic impairment: use with caution; monitor liver function tests. - Not indicated for type 1 diabetes or diabetic ketoacidosis: ineffective in insulin‑deficient states. - Concomitant sulfonylureas or insulin: increased risk of hypoglycaemia; adjust co‑medication as needed. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Vildagliptin may interact with other medicines; awareness helps prevent adverse events.

Major Interactions (Avoid): - Concurrent use with insulin or sulfonylureas: can cause severe hypoglycaemia. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels.

Moderate Interactions (Monitor Closely): - Rifampicin: may reduce vildagliptin exposure, diminishing efficacy. - Beta‑blockers: can mask hypoglycaemia symptoms, requiring closer glucose monitoring. - Diuretics (thiazides): may affect glucose tolerance, necessitating periodic assessment.